LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
OWLT
Owlet, Inc.
There isn't enough reported data to score OWLT yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OWLT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
OWLT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | โ |
| Current | 46x | $1,427 | โ |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OWLT PE Valuation
OWLT has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OWLT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect OWLT's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus OWLT down 234%.
OWLT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.20 | -$0.82 |
| Q2 2025 | -$3.75 | -$1.14 |
| Q1 2025 | -$1.68 | +$1.82 |
| Q4 2024 | -$2.30 | +$2.23 |
| Q3 2024 | -$2.38 | +$3.57 |
| Q2 2024 | -$2.61 | +$4.88 |
| Q1 2024 | -$3.50 | +$4.34 |
| Q4 2023 | -$4.53 | +$5.41 |
OWLT is still losing money, but far less than before: $3.20 per share over the past year, against $13.28 at its worst in mid-2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OWLT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OWLT on profitability, with a higher operating margin.
OWLT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $33.9M | +30% |
| Q1 2026 | $22.5M | +6.4% |
| Q4 2025 | $26.6M | +30% |
| Q3 2025 | $32M | +45% |
| Q2 2025 | $26.1M | +26% |
| Q1 2025 | $21.1M | +43% |
| Q4 2024 | $20.5M | -2.5% |
| Q3 2024 | $22.1M | +141% |
OWLT's revenue has grown year over year for six quarters in a row: $34M last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 5.1% | +13 points |
| Q1 2026 | -24% | -12 points |
| Q4 2025 | -18% | +18 points |
| Q3 2025 | 3.8% | +26 points |
| Q2 2025 | -7.4% | +3.5 points |
| Q1 2025 | -13% | +26 points |
| Q4 2024 | -36% | -22 points |
| Q3 2024 | -22% | +64 points |
OWLT's operating margin was 5.1% last quarter, up 13 points from the same quarter a year ago, near the top of its range since 2020.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OWLT on cash generation, producing positive trailing cash flow while its opponent burns cash.
OWLT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$631K | +$1.7M |
| Q1 2026 | -$5.1M | +$865K |
| Q4 2025 | -$651K | -122% |
| Q3 2025 | -$2.2M | +$5.7M |
| Q2 2025 | -$2.3M | +$1M |
| Q1 2025 | -$5.9M | -$2.6M |
| Q4 2024 | $3M | +$4.6M |
| Q3 2024 | -$7.9M | -$2.7M |
OWLT has burned cash in almost every quarter: โ$9M over the past year, against โ$13M the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OWLT Net Leverage
OWLT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OWLT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 9.3 | Oversold |
OWLT's weekly RSI is 43 (neutral) and its Stochastic is 9 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OWLT PE vs Healthcare Sector
OWLT has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over OWLT on trend strength, trading above more of its moving averages.
OWLT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.49 | 2.9% above |
| 20 week MA | $5.02 | 8% below |
| 50 week MA | $7.32 | 37% below |
| 100 week MA | $6.92 | 33% below |
| 200 week MA | $5.77 | 20% below |
OWLT has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 20% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over OWLT on returns for 2026, with the stronger performance.
OWLT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.8 | $140.8 | +3.7% |
| 2021 | $140.8 | $40.7 | -71% |
| 2022 | $40.7 | $9.57 | -77% |
| 2023 | $9.57 | $5.28 | -45% |
| 2024 | $5.28 | $4.48 | -15% |
| 2025 | $4.48 | $15.5 | +247% |
| 2026 YTD | $15.5 | $4.62 | -70% |
OWLT's yearly returns have swung widely, from +247% in 2025 to โ77% in 2022. It's down 70% so far in 2026.